Press Releases

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer

November 7, 2023

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

November 2, 2023

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer

November 10, 2022

Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value

October 18, 2022

Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors

May 5, 2022

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit

March 22, 2022

Scopus BioPharma Provides Update Following Annual Meeting of Stockholders

January 10, 2022

Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster’s Campaign Against the Company

December 17, 2021

Scopus BioPharma Sends Letter Urging Stockholders to Vote “FOR ALL” of the Company’s Director Nominees on the WHITE Proxy Card

December 7, 2021

Scopus BioPharma Announces $9.75 Million Private Placement Priced At-The-Market

November 22, 2021

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

November 8, 2021

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

October 8, 2021

Scopus BioPharma to Present at the LD Micro Main Event

October 5, 2021

Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity

October 1, 2021

Scopus BioPharma to Present at MicroCap Rodeo’s Fall Harvest Best Ideas Conference

October 1, 2021

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society

September 29, 2021

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

September 28, 2021

Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders

September 28, 2021

Scopus BioPharma to Present at the Benzinga Healthcare Small Cap Conference

September 23, 2021

Scopus BioPharma’s Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

September 22, 2021

China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform

September 21, 2021

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointments of John Rossi, Ph.D. and Nagy Habib, Ch.M., F.R.C.S. to the Scientific Advisory Board

September 14, 2021

Scopus BioPharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 9, 2021

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor

September 7, 2021

Scopus BioPharma’s Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting

September 3, 2021

Scopus BioPharma Launches Duet Therapeutics

September 2, 2021

Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company

July 12, 2021

Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune

June 30, 2021

Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders

May 31, 2021

Scopus BioPharma to Reschedule 2021 Annual Meeting of Shareholders

May 26, 2021

Scopus BioPharma Announces FDA Approval of IND Application for Lead Drug Candidate

May 24, 2021

Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate

April 26, 2021

Scopus BioPharma Finalizes Arrangements for Submission of IND Package

March 15, 2021

Scopus BioPharma Announces Closing of Underwriters’ Over-Allotment Option in Full

February 10, 2021

Underwriters Exercise Over-Allotment Option in Full, Brings Total Follow-On Public Offering Proceeds to $10.35 Million

February 8, 2021

Scopus BioPharma Announces Closing of $9 Million Follow-On Public Offering

January 29, 2021

Scopus BioPharma Announces Exchange Offer

January 27, 2021

Scopus BioPharma Announces Pricing of $9 Million Follow-On Public Offering

January 26, 2021

Scopus BioPharma Announces Completion of Clinical Lot Manufacture

January 19, 2021

Scopus BioPharma Announces Appointment of Additional Directors

December 29, 2020

Scopus BioPharma Announces Closing of Initial Public Offering

December 18, 2020

Scopus BioPharma Announces Pricing of Initial Public Offering

December 15, 2020